268 related articles for article (PubMed ID: 30923703)
21. Case-based review: pediatric medulloblastoma.
Kline CN; Packer RJ; Hwang EI; Raleigh DR; Braunstein S; Raffel C; Bandopadhayay P; Solomon DA; Aboian M; Cha S; Mueller S
Neurooncol Pract; 2017 Sep; 4(3):138-150. PubMed ID: 29692919
[TBL] [Abstract][Full Text] [Related]
22. Medulloblastoma in the age of molecular subgroups: a review.
Juraschka K; Taylor MD
J Neurosurg Pediatr; 2019 Oct; 24(4):353-363. PubMed ID: 31574483
[TBL] [Abstract][Full Text] [Related]
23. Identification of Coding and Long Noncoding RNAs Differentially Expressed in Tumors and Preferentially Expressed in Healthy Tissues.
Unfried JP; Serrano G; Suárez B; Sangro P; Ferretti V; Prior C; Boix L; Bruix J; Sangro B; Segura V; Fortes P
Cancer Res; 2019 Oct; 79(20):5167-5180. PubMed ID: 31387921
[TBL] [Abstract][Full Text] [Related]
24. Long noncoding RNAs in regulation of human breast cancer.
Wang G; Liu C; Deng S; Zhao Q; Li T; Qiao S; Shen L; Zhang Y; Lü J; Meng L; Liang C; Yu Z
Brief Funct Genomics; 2016 May; 15(3):222-6. PubMed ID: 26582840
[TBL] [Abstract][Full Text] [Related]
25. Characterization of novel biomarkers in selecting for subtype specific medulloblastoma phenotypes.
Liang L; Aiken C; McClelland R; Morrison LC; Tatari N; Remke M; Ramaswamy V; Issaivanan M; Ryken T; Del Bigio MR; Taylor MD; Werbowetski-Ogilvie TE
Oncotarget; 2015 Nov; 6(36):38881-900. PubMed ID: 26497209
[TBL] [Abstract][Full Text] [Related]
26. Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas.
Menyhárt O; Giangaspero F; Győrffy B
J Hematol Oncol; 2019 Mar; 12(1):29. PubMed ID: 30876441
[TBL] [Abstract][Full Text] [Related]
27. Role of MicroRNAs in the Development and Progression of the Four Medulloblastoma Subgroups.
Bevacqua E; Farshchi J; Niklison-Chirou MV; Tucci P
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944941
[TBL] [Abstract][Full Text] [Related]
28. Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis.
Łastowska M; Trubicka J; Niemira M; Paczkowska-Abdulsalam M; Karkucińska-Więckowska A; Kaleta M; Drogosiewicz M; Perek-Polnik M; Krętowski A; Cukrowska B; Grajkowska W; Dembowska-Bagińska B; Matyja E
J Neurooncol; 2018 Jun; 138(2):231-240. PubMed ID: 29427151
[TBL] [Abstract][Full Text] [Related]
29. High OCT4A levels drive tumorigenicity and metastatic potential of medulloblastoma cells.
da Silva PBG; Teixeira Dos Santos MC; Rodini CO; Kaid C; Pereira MCL; Furukawa G; da Cruz DSG; Goldfeder MB; Rocha CRR; Rosenberg C; Okamoto OK
Oncotarget; 2017 Mar; 8(12):19192-19204. PubMed ID: 28186969
[TBL] [Abstract][Full Text] [Related]
30. Long Noncoding RNAs in Lung Cancer.
Roth A; Diederichs S
Curr Top Microbiol Immunol; 2016; 394():57-110. PubMed ID: 26037047
[TBL] [Abstract][Full Text] [Related]
31. Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma.
Park AK; Lee JY; Cheong H; Ramaswamy V; Park SH; Kool M; Phi JH; Choi SA; Cavalli F; Taylor MD; Kim SK
BMC Cancer; 2019 Jun; 19(1):571. PubMed ID: 31185958
[TBL] [Abstract][Full Text] [Related]
32. Methylation Profiling of Medulloblastoma in a Clinical Setting Permits Sub-classification and Reveals New Outcome Predictions.
Alharbi M; Mobark N; Bashawri Y; Abu Safieh L; Alowayn A; Aljelaify R; AlSaeed M; Almutairi A; Alqubaishi F; AlSolme E; Ahmad M; Al-Banyan A; Alotabi FE; Serrano J; Snuderl M; Al-Rashed M; Abedalthagafi M
Front Neurol; 2020; 11():167. PubMed ID: 32265819
[TBL] [Abstract][Full Text] [Related]
33. Clinical implications of medulloblastoma subgroups: incidence of CSF diversion surgery.
Schneider C; Ramaswamy V; Kulkarni AV; Rutka JT; Remke M; Tabori U; Hawkins C; Bouffet E; Taylor MD
J Neurosurg Pediatr; 2015 Mar; 15(3):236-42. PubMed ID: 25525930
[TBL] [Abstract][Full Text] [Related]
34. Altered long noncoding RNA expression profiles in the myocardium of rats with ischemic heart failure.
Gao W; Wang ZM; Zhu M; Lian XQ; Zhao H; Zhao D; Yang ZJ; Lu X; Wang LS
J Cardiovasc Med (Hagerstown); 2015 Jul; 16(7):473-9. PubMed ID: 26002832
[TBL] [Abstract][Full Text] [Related]
35. A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma.
Gómez S; Garrido-Garcia A; Garcia-Gerique L; Lemos I; Suñol M; de Torres C; Kulis M; Pérez-Jaume S; Carcaboso ÁM; Luu B; Kieran MW; Jabado N; Kozlenkov A; Dracheva S; Ramaswamy V; Hovestadt V; Johann P; Jones DTW; Pfister SM; Morales La Madrid A; Cruz O; Taylor MD; Martin-Subero JI; Mora J; Lavarino C
Clin Cancer Res; 2018 Mar; 24(6):1355-1363. PubMed ID: 29351917
[No Abstract] [Full Text] [Related]
36. Current medulloblastoma subgroup specific clinical trials.
Thompson EM; Ashley D; Landi D
Transl Pediatr; 2020 Apr; 9(2):157-162. PubMed ID: 32477916
[TBL] [Abstract][Full Text] [Related]
37. Medulloblastoma: optimizing care with a multidisciplinary approach.
Thomas A; Noël G
J Multidiscip Healthc; 2019; 12():335-347. PubMed ID: 31118657
[TBL] [Abstract][Full Text] [Related]
38. Identification of CD24 as a marker of Patched1 deleted medulloblastoma-initiating neural progenitor cells.
Robson JP; Remke M; Kool M; Julian E; Korshunov A; Pfister SM; Osborne GW; Taylor MD; Wainwright B; Reynolds BA
PLoS One; 2019; 14(1):e0210665. PubMed ID: 30657775
[TBL] [Abstract][Full Text] [Related]
39. Medulloblastoma, WNT-activated/SHH-activated: clinical impact of molecular analysis and histogenetic evaluation.
Cambruzzi E
Childs Nerv Syst; 2018 May; 34(5):809-815. PubMed ID: 29582169
[TBL] [Abstract][Full Text] [Related]
40. The Roles of miRNAs in Medulloblastoma: A Systematic Review.
Mollashahi B; Aghamaleki FS; Movafagh A
J Cancer Prev; 2019 Jun; 24(2):79-90. PubMed ID: 31360688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
